Oxford University Press

SHERPA: Yellow

People

  1. Rosenberg
    Rosenberg
  2. Bajorin
    Bajorin
  3. Iyer
    Iyer
  4. Baxi
    Baxi
  5. Berger
    Berger
  6. Bochner
    Bochner
  7. Cambria
    Cambria
  8. Chakravarty
    Chakravarty
  9. D'Andrea-Carlino
    D'Andrea-Carlino
  10. Feldman
    Feldman

Groups

  1. Department of Medicine (39)
  2. Genitourinary Oncology Service (39)
  3. Solid Tumor Oncology Division (39)
  4. Epidemiology and Biostatistics (2)
  5. GSK Faculty (2)
  6. Melanoma and Immunotherapeutics Service (2)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (1)
  8. Biostatistics Service (1)
  9. Breast Medicine Service (1)
  10. Computational Oncology Service (1)
Search Within
  1. "Jonathan Rosenberg"
Formats
  1. Meeting Abstract (31)
  2. Journal Article (7)
  3. Guidelines (1)
Groups
  1. Department of Medicine (39)
  2. Genitourinary Oncology Service (39)
  3. Solid Tumor Oncology Division (39)
  4. Epidemiology and Biostatistics (2)
  5. GSK Faculty (2)
  6. Melanoma and Immunotherapeutics Service (2)

More Groups

People
  1. Jonathan Rosenberg (39)
  2. Dean Bajorin (3)
  3. Gopakumar Iyer (3)
  4. Margaret Callahan (2)
  5. Alexia Iasonos (1)
  6. Alison Schram (1)

More People

Years
  1. 2023 (2)
  2. 2022 (1)
  3. 2021 (2)
  4. 2020 (3)
  5. 2019 (6)
  6. 2018 (9)

More Years

Publications
  1. Annals of Oncology (38)
  2. JNCI: Journal of the National Cancer Institute (1)

Results (39)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Study EV-103 cohort L: Perioperative treatment w/ enfortumab vedotin (EV) monotherapy in cisplatin (cis)ineligible patients (pts) w/ muscle invasive bladder cancer (MIBC)
    Meeting Abstract

    Sridhar, S.; O'Donnell, P. H.; Flaig, T. W.; Rosenberg, J. E.; Hoimes, C. J.; Milowsky, M. I.; Srinivas, S.; George, S.; McKay, R. R.; Petrylak, D. P.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma
    Journal Article

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Annals of Oncology (2023)

    Fulltext@MSK | Save
  • Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC)
    Meeting Abstract

    Rosenberg, J. E.; Milowsky, M.; Ramamurthy, C.; Mar, N.; McKay, R. R.; Friedlander, T.; Ferrario, C.; Bracarda, S.; George, S.; Moon, H.; more...
    Annals of Oncology (2022)

    Fulltext@MSK | Save
  • Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
    Meeting Abstract

    Rosenberg, J. E.; Galsky, M. D.; Balar, A. V.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Srinivas, S.; Drakaki, A.; Javery, A.; Nelson, B.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
    Meeting Abstract

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC): Extended follow-up from CheckMate 032
    Meeting Abstract

    Sharma, P.; Siefker-Radtke, A. O.; de Braud, F.; Basso, U.; Calvo, E.; Bono, P.; Morse, M.; Ascierto, P. A.; Lopez-Martin, J.; Brossart, P.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • EV-201: Long-term results of enfortumab vedotin monotherapy for locally advanced or metastatic urothelial cancer previously treated with platinum and PD-1/PD-L1 inhibitors
    Meeting Abstract

    O'Donnell, P.; Galsky, M. D.; Rosenberg, J. E.; Petrylak, D. P.; Balar, A. V.; McGregor, B. A.; Heath, E.; Yu, E. Y.; Quinn, D. I.; Hahn, N. M.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Sitravatinib (sitra) in combination with nivolumab (nivo) demonstrates clinical activity in checkpoint inhibitor (CPI) naive, platinum-experienced patients (pts) with advanced or metastatic urothelial carcinoma (UC)
    Meeting Abstract

    Msaouel, P.; Siefker-Radtke, A. O.; Sweis, R.; Mao, S.; Rosenberg, J. E.; Vaishampayan, U. N.; Rezazadeh Kalebasty, A.; Pili, R.; Bupathi, M.; Nordquist, L. T.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • EV-301: A phase III trial in progress evaluating enfortumab vedotin versus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma
    Meeting Abstract

    Petrylak, D. P.; Rosenberg, J. E.; Lee, J.; Yonese, J.; Duran, I.; Loriot, Y.; Sonpavde, G.; Wu, C.; Gartner, E. M.; Melhem-Bertrandt, A.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save
  • EAU-ESMO consensus statements on the management of advanced and variant bladder cancer - An international collaborative multi-stakeholder effort: Under the auspices of the EAU and ESMO Guidelines Committees†
    Guidelines

    Horwich, A.; Babjuk, M.; Bellmunt, J.; Bruins, H. M.; De Reijke, T. M.; De Santis, M.; Gillessen, S.; James, N.; Maclennan, S.; Palou, J.; more...
    Annals of Oncology (2019)

    Fulltext@MSK | Save